Zura Bio Limited (ZURA) Stock Price, News, Quote & History
WebZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual ...
Zura Bio Ltd (ZURA) Stock Price & News - Google Finance
WebGet the latest Zura Bio Ltd (ZURA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Zura Bio Limited (ZURA) Stock Price, Quote & News - Stock Analysis
Web5 days ago · HENDERSON, Nev.-- (BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammator... 26 days ago - Business Wire. Zura Bio Announces Robert Lisicki as CEO and Director.
Zura Bio Reports First Quarter 2024 Financial Results and Recent ...
WebHENDERSON, Nev., May 09, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and ...
Zura Bio Limited (ZURA) Latest Stock News & Headlines - Yahoo …
WebGet the latest Zura Bio Limited (ZURA) stock news and headlines to help you in your trading and investing decisions.
Zura Bio (ZURA) Stock Price, News & Analysis - MarketBeat
Web6 days ago · Should You Buy or Sell Zura Bio Stock? Get The Latest ZURA Stock Analysis, Price Target, Headlines, and Short Interest at MarketBeat.
ZURA Stock Quote Price and Forecast | CNN
WebView Zura Bio Limited Class A ZURA stock quote prices, financial information, real-time forecasts, and company news from CNN.
Zura Bio stock jumps on plans to raise $112.5M in private financing
WebApr 18, 2024 · Zura Bio ( NASDAQ: ZURA) shares jumped around 12% on Thursday after the immunology company entered into subscription agreements for a private placement to raise around $112.5M in gross proceeds.
Zura Bio Limited (ZURA) Upgraded to Buy: Here's What You …
Web5 days ago · Earnings Estimate Revisions for Zura Bio Limited. This company is expected to earn -$0.63 per share for the fiscal year ending December 2024, which represents a year-over-year change of 69.9% ...
Zura to license autoimmune disease drug from Lilly; plans $80M …
WebApr 27, 2023 · Zura Bio ( NASDAQ: ZURA) is licensing potential autoimmune disease drug tibulizumab from Eli Lilly ( NYSE: LLY ). Tibulizumab, which will be called ZB-106, has clinical data from two phase 1b...
Skip to content